Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses
- Duke Univ. Medical Center, Durham, NC (United States)
- Univ. of Montreal, Quebec (Canada)
- Kamuzu Central Hospital, Lilongwe (Malawi). Univ. of North Carolina Project
- Univ. of North Carolina, Chapel Hill, NC (United States)
- Kilimanjaro Christian Medical Center, Moshi (Tanzania)
- London School of Hygiene and Tropical Medicine, London (United Kingdom)
- National Inst. for Communicable Diseases, Johannesburg (South Africa)
- Duke Univ. Medical Center, Durham, NC (United States); National Inst. for Communicable Diseases, Johannesburg (South Africa)
- New York Univ. School of Medicine, New York, NY (United States)
- National Inst. of Health (NIH), Bethesda, MD (United States). Vaccine Research Center
- Univ. of Pennsylvania, Philadelphia, PA (United States). Perelman School of Medicine
- Harvard Medical School, Boston, MA (United States). Dana-Farber Cancer Inst.
- Los Alamos National Lab. (LANL), Los Alamos, NM (United States)
The third variable (V3) loop and the CD4 binding site (CD4bs) of the viral envelope are frequently targeted by neutralizing antibodies (nAbs) in HIV-1-infected individuals. In chronic infection, virus escape mutants repopulate the plasma and V3 and CD4bs nAbs emerge that can neutralize heterologous tier 1 easy-to-neutralize, but not tier 2 difficult-to-neutralize HIV-1 isolates. However, neutralization sensitivity of autologous plasma viruses to this type of nAb response has not been studied. We describe the development and evolution in vivo of antibodies distinguished by their target specificity for V3and CD4bs epitopes on autologous tier 2 viruses but not on heterologous tier 2 viruses. A surprisingly high fraction of autologous circulating viruses was sensitive to these antibodies. These findings demonstrate a role for V3 and CD4bs antibodies in constraining the native envelope trimer in vivo to a neutralization-resistant phenotype, explaining why HIV-1 transmission generally occurs by tier 2 neutralization-resistant viruses.
- Research Organization:
- Los Alamos National Laboratory (LANL), Los Alamos, NM (United States)
- Sponsoring Organization:
- USDOE
- Grant/Contract Number:
- AC52-06NA25396
- OSTI ID:
- 1233164
- Report Number(s):
- LA-UR-14-24938; PII: S1931312815003340
- Journal Information:
- Cell Host & Microbe, Vol. 18, Issue 3; ISSN 1931-3128
- Publisher:
- ElsevierCopyright Statement
- Country of Publication:
- United States
- Language:
- English
Web of Science
Similar Records
Escape from Autologous Neutralizing Antibodies in Acute/Early Subtype C HIV-1 Infection Requires Multiple Pathways
Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site